Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.8K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

593
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
593
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

339
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
339
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Inflammation01:38

Inflammation

64.9K
Overview
64.9K
iPS Cell Differentiation01:22

iPS Cell Differentiation

3.3K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Elevated allostatic load, adverse body composition, and reduced overall survival in a retrospective cohort of men with newly diagnosed metastatic prostate cancer.

Journal of the Academy of Nutrition and Dietetics·2026
Same author

Intravenous Dexamethasone for Serous Retinal Detachment After Laser Ablation for Retinopathy of Prematurity.

Journal of vitreoretinal diseases·2026
Same author

Electoral politics influence expansion and titling of informal urban settlements.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Prognostic value of nuclear versus cytoplasmic cyclin D1 in human prostate cancer.

Human pathology·2026
Same author

Ex-utero intrapartum treatment of a breech fetus: a case report and review of the literature.

Journal of perinatal medicine·2026
Same author

Genomic approaches to accelerate American chestnut restoration.

Science (New York, N.Y.)·2026
Same journal

Toxicity assessment of nanocosmetics: techniques and necessity for safety evaluation.

Cutaneous and ocular toxicology·2026
Same journal

Evaluation of the interrelationship between inflammatory markers, rosacea, ocular symptoms, and migraine comorbidity.

Cutaneous and ocular toxicology·2026
Same journal

Evaluation of sun-protective behaviors in geriatric patients with and without skin cancer.

Cutaneous and ocular toxicology·2026
Same journal

Ambient fine particulate matter (PM2.5) induces AhR-dependent proinflammatory responses and reactive oxygen species production in human conjunctival epithelial cells.

Cutaneous and ocular toxicology·2026
Same journal

Effects of a topical zinc oxide-<i>Momordica charantia</i> oil formulation on wound healing in diabetic and non-diabetic rats.

Cutaneous and ocular toxicology·2026
Same journal

The development of a computational model for predicting sensitization potential in cosmetics.

Cutaneous and ocular toxicology·2026
See all related articles

Related Experiment Video

Updated: Apr 10, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Statin intervention does not slow early-intermediate stage AMD progression.

Clayton Kirk1, Erica Smith1, Amy Wozniak2

  • 1Department of Ophthalmology, Loyola University Health Science Division, Maywood, IL, USA.

Cutaneous and Ocular Toxicology
|April 8, 2026
PubMed
Summary
This summary is machine-generated.

Statins do not appear to prevent the progression of early-intermediate dry age-related macular degeneration (AMD), even in patients with vascular comorbidities. This study found no significant benefit of statin intervention for managing AMD progression.

Keywords:
AMDMacularclinicalretrospectivestatin

More Related Videos

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.7K
Author Spotlight: Unraveling the Pathogenesis of Age-Related Macular Degeneration and Discovering Potential Therapies
06:16

Author Spotlight: Unraveling the Pathogenesis of Age-Related Macular Degeneration and Discovering Potential Therapies

Published on: July 28, 2023

3.2K

Related Experiment Videos

Last Updated: Apr 10, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.7K
Author Spotlight: Unraveling the Pathogenesis of Age-Related Macular Degeneration and Discovering Potential Therapies
06:16

Author Spotlight: Unraveling the Pathogenesis of Age-Related Macular Degeneration and Discovering Potential Therapies

Published on: July 28, 2023

3.2K

Area of Science:

  • Ophthalmology
  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Emerging evidence suggests statins may protect against dry age-related macular degeneration (AMD) progression.
  • However, clinical data on statin efficacy for early-intermediate AMD remains inconclusive.

Purpose of the Study:

  • To evaluate the effect of statin intervention on the progression of early-intermediate stage non-neovascular (dry) AMD.
  • To determine if vascular comorbidities influence the efficacy of statins in AMD management.

Main Methods:

  • Retrospective review of 10,026 patient encounters over 10 years (2009-2019).
  • Analysis of 1579 patients diagnosed with early-intermediate AMD, noting vascular comorbidities and statin use.
  • Statistical analysis using hazard ratios (HR) and confidence intervals (CI).

Main Results:

  • 68% of early-intermediate AMD patients with vascular comorbidities received statin intervention.
  • Statin use did not significantly alter AMD progression, regardless of vascular comorbidity (HR = 0.97, 95% CI = 0.73-1.28, p=0.82).
  • Early-intermediate AMD patients with vascular comorbidities were not at increased risk for AMD progression.

Conclusions:

  • Findings do not support the prophylactic use of statins to slow or prevent early-intermediate AMD progression.
  • Statin intervention for LDL cholesterol management showed no benefit in this patient cohort.